https://www.selleckchem.com/products/cpi-613.html
unded through a grant from the Bill Melinda Gates Foundation to the Liverpool School of Hygiene and Tropical Medicine. To evaluate whether proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) is associated with cardiovascular and safety events in statin-treated patients with cardiovascular risk. Electronic databases (Pubmed, Cochrane, MEDLINE, EMBASE, ClinicalTrials.gov) were searched through March 31, 2020. Included randomized clinical trials (RCTs) compared PCSK9i use with no PCSK9i in statin treated patients. Two in
Beğen
Yorum Yap
Paylaş
